These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 29103140

  • 1. Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.
    Yoo M, Yoo M, Kim JE, Lee HK, Lee CO, Park CH, Jung KY.
    Arch Pharm Res; 2018 Jan; 41(1):46-56. PubMed ID: 29103140
    [Abstract] [Full Text] [Related]

  • 2. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J, Wang Y, Li Y, Xu L, Cao D, Song S, Damaneh MS, Wang X, Meng T, Chen YL, Shen J, Miao Z, Xiong B.
    Eur J Med Chem; 2017 Sep 08; 137():176-195. PubMed ID: 28586718
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors.
    Yang Y, Zhao L, Xu B, Yang L, Zhang J, Zhang H, Zhou J.
    Bioorg Chem; 2016 Oct 08; 68():236-44. PubMed ID: 27580186
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y, Xiao S, Chen Y, Jiang H, Liu N, Luo C, Chen S, Chen H.
    Eur J Med Chem; 2018 May 25; 152():264-273. PubMed ID: 29730189
    [Abstract] [Full Text] [Related]

  • 5. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
    Kong B, Zhu Z, Li H, Hong Q, Wang C, Ma Y, Zheng W, Jiang F, Zhang Z, Ran T, Bian Y, Yang N, Lu T, Zhu J, Tang W, Chen Y.
    Eur J Med Chem; 2022 Jan 05; 227():113953. PubMed ID: 34731760
    [Abstract] [Full Text] [Related]

  • 6. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J, Zou W, Yu K, Liu B, Liang W, Wang L, Lu Y, Jiang Z, Wang A, Zhu J.
    J Enzyme Inhib Med Chem; 2021 Dec 05; 36(1):903-913. PubMed ID: 33820450
    [Abstract] [Full Text] [Related]

  • 7. Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
    Zhao L, Wang Y, Cao D, Chen T, Wang Q, Li Y, Xu Y, Zhang N, Wang X, Chen D, Chen L, Chen YL, Xia G, Shi Z, Liu YC, Lin Y, Miao Z, Shen J, Xiong B.
    J Med Chem; 2015 Feb 12; 58(3):1281-97. PubMed ID: 25559428
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.
    Yang Y, Chen P, Zhao L, Zhang B, Xu C, Zhang H, Zhou J.
    Bioorg Med Chem; 2021 Jan 01; 29():115857. PubMed ID: 33191086
    [Abstract] [Full Text] [Related]

  • 9. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
    Li X, Zhang J, Zhao L, Yang Y, Zhang H, Zhou J.
    ChemMedChem; 2018 Jul 06; 13(13):1363-1368. PubMed ID: 29808961
    [Abstract] [Full Text] [Related]

  • 10. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
    Zhang Z, Hou S, Chen H, Ran T, Jiang F, Bian Y, Zhang D, Zhi Y, Wang L, Zhang L, Li H, Zhang Y, Tang W, Lu T, Chen Y.
    Bioorg Med Chem Lett; 2016 Jun 15; 26(12):2931-2935. PubMed ID: 27142751
    [Abstract] [Full Text] [Related]

  • 11. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW, Hattersley MM, Yao Y, Dulak A, Wang W, Petteruti P, Dale IL, Boiko S, Cheung T, Zhang J, Wen S, Castriotta L, Lawson D, Collins M, Bao L, Ahdesmaki MJ, Walker G, O'Connor G, Yeh TC, Rabow AA, Dry JR, Reimer C, Lyne P, Mills GB, Fawell SE, Waring MJ, Zinda M, Clark E, Chen H.
    Mol Cancer Ther; 2016 Nov 15; 15(11):2563-2574. PubMed ID: 27573426
    [Abstract] [Full Text] [Related]

  • 12. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
    Shao M, He L, Zheng L, Huang L, Zhou Y, Wang T, Chen Y, Shen M, Wang F, Yang Z, Chen L.
    Bioorg Med Chem Lett; 2017 Sep 01; 27(17):4051-4055. PubMed ID: 28765013
    [Abstract] [Full Text] [Related]

  • 13. A natural compound, aristoyagonine, is identified as a potent bromodomain inhibitor by mid-throughput screening.
    Kim YH, Kim M, Yoo M, Kim JE, Lee HK, Heo JN, Lee CO, Yoo M, Jung KY, Yun CS, Moon SW, Chang HK, Chung CW, Pyo S, Choi SU, Park CH.
    Biochem Biophys Res Commun; 2018 Sep 05; 503(2):882-887. PubMed ID: 29928885
    [Abstract] [Full Text] [Related]

  • 14. Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors.
    Cui J, Peng X, Gao D, Dai Y, Ai J, Li Y.
    Bioorg Med Chem Lett; 2017 Aug 15; 27(16):3782-3786. PubMed ID: 28687204
    [Abstract] [Full Text] [Related]

  • 15. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, Schäfer BW, Burdach S, Richter GH.
    Oncotarget; 2016 Jan 12; 7(2):1451-63. PubMed ID: 26623725
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.
    Feng Z, Chen A, Shi J, Zhou D, Shi W, Qiu Q, Liu X, Huang W, Li J, Qian H, Zhang W.
    Bioorg Chem; 2021 Jun 12; 111():104849. PubMed ID: 33798846
    [Abstract] [Full Text] [Related]

  • 17. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X, Zhang Y, Liu Z, Song M, Xing Y, Xiang Q, Wang Z, Tu Z, Zhou Y, Ding K, Xu Y.
    J Med Chem; 2016 Feb 25; 59(4):1565-79. PubMed ID: 26731490
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis and biological evaluation of novel 1H-1,2,4-triazole, benzothiazole and indazole-based derivatives as potent FGFR1 inhibitors viafragment-based virtual screening.
    Liu J, Wen Y, Gao L, Gao L, He F, Zhou J, Wang J, Dai R, Chen X, Kang D, Hu L.
    J Enzyme Inhib Med Chem; 2020 Dec 25; 35(1):72-84. PubMed ID: 31682465
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
    Zhang Z, Ma P, Jing Y, Yan Y, Cai MC, Zhang M, Zhang S, Peng H, Ji ZL, Di W, Gu Z, Gao WQ, Zhuang G.
    Theranostics; 2016 Dec 25; 6(2):219-30. PubMed ID: 26877780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.